...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: RVX 2023 valuation attempt using Moderna metrics

Thanks for the attempt. I'd say it is conservative valuation / underestimation.

1. Pills cost less to produce and distribute vs. vaccines (margin much higher vs. vaccines)

2. Sales will be much higher in other countries where vaccination rate is lower vs. Canada, US, etc.

2. EPS / estimation does not reflect future sales from other indications, eg. PAH, CVD, CKD, etc.

 

 

Share
New Message
Please login to post a reply